comprehensive
Previous article:
Walensky prepares to leave CDC — and Congress — behind
Next article: Eli Lilly reports tirzepatide MASH success during Q4 earnings
Next article: Eli Lilly reports tirzepatide MASH success during Q4 earnings
explore
focus
-
Data show record exodus of life scientists from academia
2025-10-01 23:50 -
Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO
2025-10-01 23:34 -
Congress might make insulin pumps more accessible to the blind
2025-10-01 23:26 -
Latigo launches with $135 million for Vertex
2025-10-01 23:07 -
STAT Boddities: What happens to the brain when we get scared?
2025-10-01 22:51 -
Study gives hint on South Asians’ higher risk of cardiovascular disease
2025-10-01 21:28